Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection
A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750 μl), with clozapine added as internal standard, is diluted 3+1 with water and subjected to a solid-phase extrac...
Gespeichert in:
| Veröffentlicht in: | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2004-04, Vol.803 (2), p.285-292 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 292 |
|---|---|
| container_issue | 2 |
| container_start_page | 285 |
| container_title | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |
| container_volume | 803 |
| creator | Widmer, N Béguin, A Rochat, B Buclin, T Kovacsovics, T Duchosal, M.A Leyvraz, S Rosselet, A Biollaz, J Decosterd, L.A |
| description | A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750
μl), with clozapine added as internal standard, is diluted 3+1 with water and subjected to a solid-phase extraction on a C18 cartridge. After matrix components elimination with 2000
μl of water (in two aliquots of 1000
μl), imatinib is eluted with 3×500
μl MeOH. The resulting eluate is evaporated under nitrogen at room temperature and is reconstituted in 180
μl 50% methanol. A 50
μl volume is injected onto a Nucleosil 100–5
μm C18 AB column. Imatinib is analyzed using a gradient elution program with solvent mixture constituted of methanol and water containing both 0.05% ammonium acetate. Imatinib is detected by UV at 261
nm. The calibration curves are linear between 0.1 and 10
μg/ml. The limit of quantification and detection are 0.05 and 0.01
μg/ml, respectively. The mean absolute recovery of imatinib is 96%. The method is precise with mean inter-day CVs within 1.1–2.4%, and accurate (range of inter-day deviations −0.6 to +0.7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients. |
| doi_str_mv | 10.1016/j.jchromb.2004.01.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71802296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023204000285</els_id><sourcerecordid>71802296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-983710d6a7944523a27110a8fda4e0089f64d7c33138eb475bd50e49226cc83b3</originalsourceid><addsrcrecordid>eNqFkcFu1DAURSMEoqXwCSBvQLBIeLaTOFlVqIWCVIkNSOwsx35hPHLi1E5GzI59l_wHH8Gn8CV4OpFgx8pP1rnvXd2bZU8pFBRo_XpbbPUm-KErGEBZAC0A6nvZKW0Ez7mov9xPcyUgB8bZSfYoxi0AFSD4w-yEVlBzzsVpdnuJM4bBjmq2fiS-J3ZI42g78vLKIe5Qk18_XxE7ks0yqJFMTsVBkW5PonfW5NNGRST4bQ5KH1b8_v7D2ZvFGnJnT83-a1DTZp_-F5egnfUOZ6K66EOnRo3EJAd30sfZg165iE_W9yz7_O7tp4v3-fXHqw8Xb65zXVE-523DBQVTK9GWZcW4YoJSUE1vVIkATdvXpRGac8ob7EpRdaYCLFvGaq0b3vGz7MVx7xT8zYJxloONGp1TI_olSkEbYKytE1gdQR18jAF7OYUUT9hLCvLQgtzKtQV5aEEClamFpHu2Hli6Ac1f1Rp7Ap6vgIpauT6kIGz8h6sprehh0fmRwxTHzmKQUVtMoRkbUmbSePsfK38AJdytUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71802296</pqid></control><display><type>article</type><title>Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Widmer, N ; Béguin, A ; Rochat, B ; Buclin, T ; Kovacsovics, T ; Duchosal, M.A ; Leyvraz, S ; Rosselet, A ; Biollaz, J ; Decosterd, L.A</creator><creatorcontrib>Widmer, N ; Béguin, A ; Rochat, B ; Buclin, T ; Kovacsovics, T ; Duchosal, M.A ; Leyvraz, S ; Rosselet, A ; Biollaz, J ; Decosterd, L.A</creatorcontrib><description>A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750
μl), with clozapine added as internal standard, is diluted 3+1 with water and subjected to a solid-phase extraction on a C18 cartridge. After matrix components elimination with 2000
μl of water (in two aliquots of 1000
μl), imatinib is eluted with 3×500
μl MeOH. The resulting eluate is evaporated under nitrogen at room temperature and is reconstituted in 180
μl 50% methanol. A 50
μl volume is injected onto a Nucleosil 100–5
μm C18 AB column. Imatinib is analyzed using a gradient elution program with solvent mixture constituted of methanol and water containing both 0.05% ammonium acetate. Imatinib is detected by UV at 261
nm. The calibration curves are linear between 0.1 and 10
μg/ml. The limit of quantification and detection are 0.05 and 0.01
μg/ml, respectively. The mean absolute recovery of imatinib is 96%. The method is precise with mean inter-day CVs within 1.1–2.4%, and accurate (range of inter-day deviations −0.6 to +0.7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.</description><identifier>ISSN: 1570-0232</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2004.01.006</identifier><identifier>PMID: 15063337</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Analytical, structural and metabolic biochemistry ; Antineoplastic Agents - blood ; Benzamides ; Biological and medical sciences ; Chromatography, High Pressure Liquid - methods ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Gleevec ; Humans ; Imatinib ; Imatinib Mesylate ; Medical sciences ; Pharmacology. Drug treatments ; Piperazines - blood ; Pyrimidines - blood ; Reproducibility of Results ; Sensitivity and Specificity ; Spectrophotometry, Ultraviolet - methods</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004-04, Vol.803 (2), p.285-292</ispartof><rights>2004 Elsevier B.V.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-983710d6a7944523a27110a8fda4e0089f64d7c33138eb475bd50e49226cc83b3</citedby><cites>FETCH-LOGICAL-c513t-983710d6a7944523a27110a8fda4e0089f64d7c33138eb475bd50e49226cc83b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jchromb.2004.01.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15611516$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15063337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Widmer, N</creatorcontrib><creatorcontrib>Béguin, A</creatorcontrib><creatorcontrib>Rochat, B</creatorcontrib><creatorcontrib>Buclin, T</creatorcontrib><creatorcontrib>Kovacsovics, T</creatorcontrib><creatorcontrib>Duchosal, M.A</creatorcontrib><creatorcontrib>Leyvraz, S</creatorcontrib><creatorcontrib>Rosselet, A</creatorcontrib><creatorcontrib>Biollaz, J</creatorcontrib><creatorcontrib>Decosterd, L.A</creatorcontrib><title>Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750
μl), with clozapine added as internal standard, is diluted 3+1 with water and subjected to a solid-phase extraction on a C18 cartridge. After matrix components elimination with 2000
μl of water (in two aliquots of 1000
μl), imatinib is eluted with 3×500
μl MeOH. The resulting eluate is evaporated under nitrogen at room temperature and is reconstituted in 180
μl 50% methanol. A 50
μl volume is injected onto a Nucleosil 100–5
μm C18 AB column. Imatinib is analyzed using a gradient elution program with solvent mixture constituted of methanol and water containing both 0.05% ammonium acetate. Imatinib is detected by UV at 261
nm. The calibration curves are linear between 0.1 and 10
μg/ml. The limit of quantification and detection are 0.05 and 0.01
μg/ml, respectively. The mean absolute recovery of imatinib is 96%. The method is precise with mean inter-day CVs within 1.1–2.4%, and accurate (range of inter-day deviations −0.6 to +0.7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.</description><subject>Analysis</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Antineoplastic Agents - blood</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>Gleevec</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - blood</subject><subject>Pyrimidines - blood</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Spectrophotometry, Ultraviolet - methods</subject><issn>1570-0232</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAURSMEoqXwCSBvQLBIeLaTOFlVqIWCVIkNSOwsx35hPHLi1E5GzI59l_wHH8Gn8CV4OpFgx8pP1rnvXd2bZU8pFBRo_XpbbPUm-KErGEBZAC0A6nvZKW0Ez7mov9xPcyUgB8bZSfYoxi0AFSD4w-yEVlBzzsVpdnuJM4bBjmq2fiS-J3ZI42g78vLKIe5Qk18_XxE7ks0yqJFMTsVBkW5PonfW5NNGRST4bQ5KH1b8_v7D2ZvFGnJnT83-a1DTZp_-F5egnfUOZ6K66EOnRo3EJAd30sfZg165iE_W9yz7_O7tp4v3-fXHqw8Xb65zXVE-523DBQVTK9GWZcW4YoJSUE1vVIkATdvXpRGac8ob7EpRdaYCLFvGaq0b3vGz7MVx7xT8zYJxloONGp1TI_olSkEbYKytE1gdQR18jAF7OYUUT9hLCvLQgtzKtQV5aEEClamFpHu2Hli6Ac1f1Rp7Ap6vgIpauT6kIGz8h6sprehh0fmRwxTHzmKQUVtMoRkbUmbSePsfK38AJdytUw</recordid><startdate>20040425</startdate><enddate>20040425</enddate><creator>Widmer, N</creator><creator>Béguin, A</creator><creator>Rochat, B</creator><creator>Buclin, T</creator><creator>Kovacsovics, T</creator><creator>Duchosal, M.A</creator><creator>Leyvraz, S</creator><creator>Rosselet, A</creator><creator>Biollaz, J</creator><creator>Decosterd, L.A</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040425</creationdate><title>Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection</title><author>Widmer, N ; Béguin, A ; Rochat, B ; Buclin, T ; Kovacsovics, T ; Duchosal, M.A ; Leyvraz, S ; Rosselet, A ; Biollaz, J ; Decosterd, L.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-983710d6a7944523a27110a8fda4e0089f64d7c33138eb475bd50e49226cc83b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Analysis</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Antineoplastic Agents - blood</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>Gleevec</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - blood</topic><topic>Pyrimidines - blood</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Spectrophotometry, Ultraviolet - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Widmer, N</creatorcontrib><creatorcontrib>Béguin, A</creatorcontrib><creatorcontrib>Rochat, B</creatorcontrib><creatorcontrib>Buclin, T</creatorcontrib><creatorcontrib>Kovacsovics, T</creatorcontrib><creatorcontrib>Duchosal, M.A</creatorcontrib><creatorcontrib>Leyvraz, S</creatorcontrib><creatorcontrib>Rosselet, A</creatorcontrib><creatorcontrib>Biollaz, J</creatorcontrib><creatorcontrib>Decosterd, L.A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Widmer, N</au><au>Béguin, A</au><au>Rochat, B</au><au>Buclin, T</au><au>Kovacsovics, T</au><au>Duchosal, M.A</au><au>Leyvraz, S</au><au>Rosselet, A</au><au>Biollaz, J</au><au>Decosterd, L.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2004-04-25</date><risdate>2004</risdate><volume>803</volume><issue>2</issue><spage>285</spage><epage>292</epage><pages>285-292</pages><issn>1570-0232</issn><eissn>1873-376X</eissn><abstract>A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750
μl), with clozapine added as internal standard, is diluted 3+1 with water and subjected to a solid-phase extraction on a C18 cartridge. After matrix components elimination with 2000
μl of water (in two aliquots of 1000
μl), imatinib is eluted with 3×500
μl MeOH. The resulting eluate is evaporated under nitrogen at room temperature and is reconstituted in 180
μl 50% methanol. A 50
μl volume is injected onto a Nucleosil 100–5
μm C18 AB column. Imatinib is analyzed using a gradient elution program with solvent mixture constituted of methanol and water containing both 0.05% ammonium acetate. Imatinib is detected by UV at 261
nm. The calibration curves are linear between 0.1 and 10
μg/ml. The limit of quantification and detection are 0.05 and 0.01
μg/ml, respectively. The mean absolute recovery of imatinib is 96%. The method is precise with mean inter-day CVs within 1.1–2.4%, and accurate (range of inter-day deviations −0.6 to +0.7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15063337</pmid><doi>10.1016/j.jchromb.2004.01.006</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1570-0232 |
| ispartof | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004-04, Vol.803 (2), p.285-292 |
| issn | 1570-0232 1873-376X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71802296 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Analysis Analytical, structural and metabolic biochemistry Antineoplastic Agents - blood Benzamides Biological and medical sciences Chromatography, High Pressure Liquid - methods Fundamental and applied biological sciences. Psychology General pharmacology Gleevec Humans Imatinib Imatinib Mesylate Medical sciences Pharmacology. Drug treatments Piperazines - blood Pyrimidines - blood Reproducibility of Results Sensitivity and Specificity Spectrophotometry, Ultraviolet - methods |
| title | Determination of imatinib (Gleevec ®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A12%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20imatinib%20(Gleevec%20%C2%AE)%20in%20human%20plasma%20by%20solid-phase%20extraction%E2%80%93liquid%20chromatography%E2%80%93ultraviolet%20absorbance%20detection&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Widmer,%20N&rft.date=2004-04-25&rft.volume=803&rft.issue=2&rft.spage=285&rft.epage=292&rft.pages=285-292&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2004.01.006&rft_dat=%3Cproquest_cross%3E71802296%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71802296&rft_id=info:pmid/15063337&rft_els_id=S1570023204000285&rfr_iscdi=true |